Oxidative stress

Two New Research Studies Reinforce Prunes' Role in Optimal Health

Retrieved on: 
Giovedì, Maggio 9, 2024
Conditional sentence, Randomized controlled trial, Inflammation, Oxidative stress, Psyllium, News, Risk, Woman, Body mass index, Mineral, RDN, Health, Heart, BMI, CSSD, Doctor of Philosophy, Research, Vitamin, Osteoporosis, Diet, MPH, Vitamin K, Nutrient, Cardiovascular disease, Eating, Antioxidant, Pennsylvania State University, LDN, Ageing, Journal, Bone density, Frontiers, Muesli, Dietary supplement

ROSEVILLE, Calif., May 9, 2024 /PRNewswire/ -- Two newly published studies add to an already robust body of clinical research on prunes' myriad health benefits. This tasty pantry staple is a nutritional powerhouse that may benefit gut microbiome health, bone health, heart health and more. 

Key Points: 
  • This tasty pantry staple is a nutritional powerhouse that may benefit gut microbiome health, bone health, heart health and more.
  • Prunes are a nutritional powerhouse that may benefit gut microbiome health, bone health, heart health and more.
  • The increase of belly fat is common in postmenopausal women and when excessive, can be a risk factor for cardiovascular disease.
  • Findings from this research show a daily diet that includes prunes may help reduce that belly fat."

Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0

Retrieved on: 
Giovedì, Maggio 9, 2024
Sale, Randomized controlled trial, Oxidative stress, Coenzyme Q10, Mikra, Biochemistry, Partnership, Life, Attention, Human, Science, Philip Bromley, PQQ, Ageing, Dietary supplement

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to announce that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”) has partnered with Virun NutraBiosciences Inc. (“Virun”), the global leader in NutraBiosciences®1, to offer CELLF 2.0, an enhanced nutraceutical gel for improving cellular health. CELLF 2.0 is available for sale now and can be ordered directly at http://wearemikra.com/products/cellf.

Key Points: 
  • CELLF 2.0 is available for sale now and can be ordered directly at http://wearemikra.com/products/cellf .
  • “We are so excited to partner exclusively with Mikra and their CELLF brand containing Glutathione, PQQ and CoQ10.
  • Our patents and patents-pending technologies are a perfect fit for Mikra.
  • This new manufacturing partnership has enabled Mikra to improve on an already great product and also allows us to offer an annual subscription option of CELLF 2.0 at a 46% discount, while still maintaining strong margins.

Longevity Biotech, Timeline, Leads the Way in Healthy Aging Research with Groundbreaking Clinical Studies

Retrieved on: 
Lunedì, Maggio 6, 2024
Biotechnology, Other Health, Diabetes, Health, Biometrics, Oncology, Vitamins, Supplements, Research, Fitness & Nutrition, Science, Clinical Trials, Cancer, Oxidative stress, American Association of Immunologists, MD, Urolithin A, Trial of the century, Doctor of Philosophy, Entrepreneurship, Prostate cancer, Neoplasm, AAI, Patient, Infection, Notifiable disease, Immune system, Longevity, CD8

Additionally, the company has partnered on two new clinical trials in collaboration with prestigious research institutions to expand its applications of Mitopure for healthy aging.

Key Points: 
  • Additionally, the company has partnered on two new clinical trials in collaboration with prestigious research institutions to expand its applications of Mitopure for healthy aging.
  • Timeline, backed by Nestlé and L'Oréal Group investments, builds on 15 years of research and multiple clinical studies.
  • "Our mission has always been to pioneer research that unlocks clinically proven interventions to help people stay healthier for longer.
  • These results open a totally new approach to directly impact our immune cells and help restore their functionality during aging."

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

Retrieved on: 
Lunedì, Aprile 22, 2024
Amyloid, Alzheimer's disease, Jort, University, MCI, Inflammation, Oxidative stress, ARIA, News, Research, Neuroinflammation, Cognition, Doctor of Philosophy, ADAS, START, KOL, Patient, SHINE, Perception, Neuron, Antibody, Therapy, Plaque, Cerebrospinal fluid

“The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO .

Key Points: 
  • “The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO .
  • The SHINE study enrolled participants in the U.S. and several countries in Europe including The Netherlands.
  • Dr. Vijverberg reviewed the design of the SHINE study and the results of the preliminary analysis of the first 24 patients who finished six months of treatment.
  • An archive of the KOL roundtable discussion is available on the News & Events page of the Investors section of the Cognition website or may be accessed directly at the following URL: https://lifescievents.com/event/cognition/ .

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

Retrieved on: 
Venerdì, Aprile 19, 2024
FDA, Safety, Inflammation, Oxidative stress, United, Armada, MD, Vaccine, Disease, Lipid metabolism, Gundersen Health System, Geographic atrophy, Clinical trial, Pharmaceutical industry

“We are very enthusiastic about the potential of OCU410 as a one-time, gene-agnostic option for the treatment of GA,” said Dr. Huma Qamar, Chief Medical Officer of Ocugen.

Key Points: 
  • “We are very enthusiastic about the potential of OCU410 as a one-time, gene-agnostic option for the treatment of GA,” said Dr. Huma Qamar, Chief Medical Officer of Ocugen.
  • Up to 13 leading retinal surgery centers across the United States are participating in the ArMaDa clinical trial.
  • The ArMaDa Phase 1/2 clinical trial will assess the safety of unilateral subretinal administration of OCU410 in subjects with GA and will be conducted in two phases.
  • The Company will continue to provide clinical updates on an ongoing basis.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
Mercoledì, Aprile 17, 2024
Molecule, Neuroimaging, American Academy, Brain, Iron, Oxidative stress, MSA, AFL, Poster, Disease, Vanderbilt University, Substantia nigra, Plasma, ASX, Pathology, Neurofilament, Forecasting, Macaque, Nerve, Multiple system atrophy, Patient, Treatment, Observational study, AAN, CSF, Neuron, Biomarker, Annual general meeting, Vanderbilt University Medical Center, Therapy, Cerebrospinal fluid, Parkinsonism, ATH, Frasier, SAN, Medical imaging

MELBOURNE, Australia and SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.

Key Points: 
  • Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.
  • At AAN we reported the baseline characteristics from our ATH434-201 Phase 2 trial including fluid biomarkers and neuroimaging data.
  • The data showed increased iron in areas of pathology and elevated plasma Neurofilament Light Chain (NfL) levels at baseline that correlated significantly with disease severity.
  • Plasma NfL significantly increased over 12 months, and both plasma and CSF NfL were associated with disease progression in MSA.

Unlocking the Secrets to a Sharper Mind and Healthier Cells

Retrieved on: 
Mercoledì, Aprile 17, 2024
Brain, Oxidative stress, Dementia, CDC, Motivation, Cell, Research, History, Nutrient, Cell membrane, Ageing

“Our bodies and brains are under constant barrage from environmental toxins and lifestyle choices that significantly harm our cellular health,” explains Return Healthy’s CEO, Dr. Werner Vosloo, ND.

Key Points: 
  • “Our bodies and brains are under constant barrage from environmental toxins and lifestyle choices that significantly harm our cellular health,” explains Return Healthy’s CEO, Dr. Werner Vosloo, ND.
  • These products replenish essential nutrients, enhance cellular repair mechanisms, and protect against oxidative stress.
  • They are pivotal for maintaining cell membrane integrity, which is essential for the brain cells that manage information processing and cognitive performance.
  • Return Healthy’s Cell Stabilization Plan is a testament to the company’s commitment to empower individuals to take control of their healthspan with preventive self-care and advanced nutritional support.

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

Retrieved on: 
Martedì, Aprile 16, 2024
Stanford University, FDA, Johns Hopkins University, University, Oxidative stress, Investment, Retinitis pigmentosa, OIS, Publication, Epidemiology, Statistics, Biomedical engineering, Pfizer, Biomedicine, Therapy, Senior, MPH, Acquisition, Cataract, Ophthalmology, Partnership, Management

“We’re thrilled to welcome Dr. Cunningham to our board of directors,” said Halden Conner, Chairman, CEO and Co-Founder of Nacuity Pharmaceuticals.

Key Points: 
  • “We’re thrilled to welcome Dr. Cunningham to our board of directors,” said Halden Conner, Chairman, CEO and Co-Founder of Nacuity Pharmaceuticals.
  • He is also an internationally recognized specialist in infectious and inflammatory eye disease with over 400 publications.
  • “Nacuity’s approach to treating ophthalmic and non-ophthalmic disorders is both completely novel and tremendously promising,” said Dr. Cunningham.
  • Dr. Cunningham is a member of the board of directors of Galera Therapeutics and Executive Chairman of Eyconis.

T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured

Retrieved on: 
Venerdì, Aprile 12, 2024
Oxidative stress, Kidney, Burn, Odense University Hospital, DKK, Patient, Immune system, Clinical trial, Cancer, Cervical cancer, Pharmaceutical industry

SØBORG, Denmark, April 12, 2024 (GLOBE NEWSWIRE) -- Cbio A/S – Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates.

Key Points: 
  • SØBORG, Denmark, April 12, 2024 (GLOBE NEWSWIRE) -- Cbio A/S – Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates.
  • Ulrik Cordes, Founder & CEO of Cbio, stated: “2023 was another great year for Cbio.
  • We finalized the preclinical development of our lead T-cell therapy asset, novoleucel and made considerable progress in preparing for our upcoming phase I/II clinical trial at Karolinska, where we will treat 20 patients with late-stage cervical cancer.
  • Ulrik Cordes continues: “Our top priority for 2024 is to start our first clinical trial, thereby reaching a major value inflection point.

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Retrieved on: 
Venerdì, Aprile 26, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Doctor of Philosophy, COYA, Reactive oxygen species, Oxidative stress, Houston Methodist Hospital, HMH, Survival, ROS, Death, Disease, Patient, Medulla oblongata, ALS, Diagnosis, Associate, Therapy, Pharmaceutical industry

The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.

Key Points: 
  • The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.
  • Reactive oxygen species (ROS) are generated mainly as byproducts of mitochondrial respiration and are tightly controlled by multiple anti-oxidant mechanisms.
  • In neurodegenerative diseases, such as ALS, when the antioxidant system is overwhelmed by overproduction of ROS, oxidative stress occurs.
  • 4-HNE, an abundant and reactive oxygen species, is thought to exert neuronal toxicity ultimately through formation of toxic protein aggregates, as seen in ALS patients.